Flexion Therapeutics Granted Fast Track Status by the FDA for FX006 for Treatment of Osteoarthritis of the Knee
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Northland Capital Markets Remains Bullish on Flexion Therapeutics (FLXN) After Being Granted Fast Track Status by FDA
September 2, 2015 9:37 AM EDTNorthland Capital Markets reiterated an Outperform rating and $40.00 price target on Flexion Therapeutics (NASDAQ: FLXN) as the company has been granted fast track status by the FDA for FX006. This reduces the NDA review time to approval to within 6 months versus the standard 10... More
Flexion Therapeutics' (FLXN) FX006 Granted Fast Track Status
September 1, 2015 4:02 PM EDTFlexion Therapeutics, Inc. (Nasdaq: FLXN) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for FX006, Flexion's late-stage, lead drug candidate that is designed as a treatment for the more than four million U.S. patients receiving intra-articular (IA) injections for osteoarthritis (OA) of the knee. Flexion is currently studying FX006 in a Phase 2b pivotal trial, with top-line data expected to be announced soon, as well as in a Phase 3 clinical trial for which it expects to share data in the first quarter of... More
